DexCom, Inc. (NASDAQ:DXCM) will be releasing its earnings data after the market closes on Tuesday, August 1st. Analysts expect DexCom to post earnings of ($0.21) per share for the quarter.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The business had revenue of $142.30 million during the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. On average, analysts expect DexCom to post $-0.68 EPS for the current fiscal year and $0.06 EPS for the next fiscal year.
Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 67.05 on Friday. The company’s market cap is $5.79 billion. The company has a 50 day moving average price of $72.63 and a 200 day moving average price of $75.71. DexCom, Inc. has a 52 week low of $57.68 and a 52 week high of $96.38.
In other news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $71.93, for a total transaction of $230,176.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $69.47, for a total value of $100,731.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,331 shares of company stock valued at $2,548,619. Corporate insiders own 1.70% of the company’s stock.
A number of research analysts recently issued reports on DXCM shares. B. Riley reiterated a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Thursday, April 27th. BidaskClub downgraded DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. BMO Capital Markets reiterated a “buy” rating and set a $105.00 price objective on shares of DexCom in a report on Thursday, July 13th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. Finally, William Blair reiterated an “outperform” rating on shares of DexCom in a report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $89.47.
WARNING: “DexCom, Inc. (DXCM) Set to Announce Earnings on Tuesday” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/07/30/dexcom-inc-dxcm-set-to-announce-earnings-on-tuesday.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.